ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1326

Efficacy of Different Biologic Agents for Improving Physical Function As Measured by the Health Assessment Questionnaire: A Meta-Analysis with Indirect Comparisons

Lillian J. Barra1, Andrew Ha2, Louise Sun3, Catarina Fonseca4 and Janet E. Pope5, 1Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, 2The University of Toronto, Toronto, ON, Canada, 3University of Ottawa, Ottawa, ON, Canada, 4Universidade de Lisboa, Lisbon, Portugal, 5Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-TNF therapy, Health Assessment Questionnaire, Rheumatoid arthritis (RA), rituximab and tocilizumab

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose:  

The Health Assessment Questionnaire (HAQ) is a patient-centred, validated measure of physical function. It is predictive for disability, morbidity and mortality. The efficacy of various biologics agents for improving HAQ in patients with Rheumatoid arthritis (RA) has been demonstrated in numerous trials. However, head-to-head comparisons of biologic agents are scarce. The objective of this study was to determine the comparative efficacy of biologic agents for improving HAQ in patients with established RA who failed Disease Modifying Anti-Rheumatic Drugs (DMARDs) or anti-Tumour Necrosis Factor alpha (TNF) agents and in patients with early RA (ERA).

Methods: We performed random effects meta-analyses (Mantel-Haenszel method) of randomized, placebo-controlled trials. Inclusion criteria were: age >15 years, clinically utilized biologic agents, HAQ score at baseline and 6 or 12 months. We searched PubMed, EMBASE and the Cochrane Library. Outcome was the mean difference in change in HAQ for biologic agents compared to controls (DHAQB–DHAQC). Indirect comparisons of the different biologic drugs compared to the control group were conducted using the Q-test based on analysis of variance.  Meta-regression was performed using the method of moments.

Results:

31 trials were included: 23 with DMARD-failures; 5 with anti-TNF-failures and 6 ERA. The following biologics were represented: abatacept, adalimumab, certolizumab, etanercept, golimumab, infliximab, rituximab and tocilizumab. In established RA patients with DMARD failures: DHAQB–DHAQC = -0.28; 95%CI:-0.324, -0.237 (I2=64%); abatacept and infliximab were less effective compared to the other anti-TNF agents and tocilizumab (p<0.01). In anti-TNF-failures: DHAQB–DHAQC was -0.254; 95%CI: -0.46, -0.049 (I2=92%); golimumab was not effective compared to control and abatacept was superior to tocilizumab (p=0.0184); rituximab was equivalent to abatacept and tocilizumab. Heterogeneity was predominately due to differences in the efficacy of the different biologic agents. In ERA trials: DHAQB–DHAQC = -0.231; 95% CI: -0.323, -0.14 (I2=0%); adalimumab, etanercept, infliximab and rituximab were equally effective. Using meta-regression, baseline HAQ did not significantly effect HAQ improvement.      

Conclusion:  

Biologic agents were efficacious at lowering HAQ in established RA and ERA by at least the minimally clinically important difference of 0.22. However, infliximab and abatacept were less effective in DMARD-failures. The role of anti-TNF agents in anti-TNF failures and of biologics in DMARD-naïve patients remains unclear.


Disclosure:

L. J. Barra,
None;

A. Ha,
None;

L. Sun,
None;

C. Fonseca,
None;

J. E. Pope,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-different-biologic-agents-for-improving-physical-function-as-measured-by-the-health-assessment-questionnaire-a-meta-analysis-with-indirect-comparisons/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology